Eisai Creates US Subsidiary H3 Biomedicine with up to $200M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Japanese drug firm Eisai has launched US subsidiary H3 Biomedicine with up to $200 million in funding to develop new oncology drugs based on patient genetic information.

Based in Cambridge, Mass., H3 Biomedicine aims to take a personalized medicine approach to developing such drugs by leveraging new insights into the genetic basis of cancer and advances in modern chemistry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.